Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $114,034 | 29 | 54.4% |
| Travel and Lodging | $89,556 | 41 | 42.7% |
| Food and Beverage | $4,476 | 36 | 2.1% |
| Honoraria | $1,500 | 1 | 0.7% |
| Education | $64.54 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novo Nordisk AS | $135,519 | 40 | $0 (2024) |
| Novo Nordisk Inc | $45,614 | 38 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $15,542 | 3 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $11,109 | 18 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $618.81 | 1 | $0 (2023) |
| Lupin Inc. | $375.00 | 1 | $0 (2018) |
| Kowa Pharmaceuticals America, Inc. | $341.67 | 2 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $142.21 | 2 | $0 (2017) |
| Eli Lilly and Company | $139.34 | 1 | $0 (2023) |
| Lilly USA, LLC | $117.27 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $27,111 | 24 | Novo Nordisk Inc ($10,364) |
| 2023 | $48,268 | 29 | Novo Nordisk AS ($34,082) |
| 2022 | $37,928 | 9 | Novo Nordisk AS ($21,497) |
| 2021 | $9,302 | 9 | Novo Nordisk AS ($5,100) |
| 2020 | $5,100 | 2 | Novo Nordisk AS ($5,100) |
| 2019 | $35,298 | 16 | Novo Nordisk Inc ($18,696) |
| 2018 | $36,491 | 13 | Novo Nordisk AS ($35,774) |
| 2017 | $10,134 | 7 | Novo Nordisk AS ($9,967) |
All Payment Transactions
109 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $73.67 | General |
| 11/13/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $93.51 | General |
| 11/04/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $117.91 | General |
| 10/20/2024 | Novo Nordisk AS | — | Consulting Fee | Cash or cash equivalent | $6,281.25 | General |
| 10/20/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $593.42 | General |
| 10/20/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $208.81 | General |
| 10/20/2024 | Novo Nordisk AS | — | Food and Beverage | In-kind items and services | $202.51 | General |
| 10/20/2024 | Novo Nordisk AS | — | Travel and Lodging | In-kind items and services | $110.50 | General |
| 10/01/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 08/23/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $117.27 | General |
| Category: Obesity | ||||||
| 05/16/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $121.42 | General |
| 03/01/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,432.50 | General |
| 03/01/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,546.00 | General |
| 03/01/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,182.00 | General |
| 03/01/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $49.10 | General |
| 03/01/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $23.40 | General |
| 02/28/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $81.39 | General |
| 02/23/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $42.50 | General |
| 02/15/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $89.30 | General |
| 02/15/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $21.44 | General |
| 01/12/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $31.15 | General |
| 01/05/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $79.25 | General |
| 01/01/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $6,375.00 | General |
| 01/01/2024 | Novo Nordisk Inc | — | Consulting Fee | Cash or cash equivalent | $3,187.50 | General |
| 12/31/2023 | Regeneron Healthcare Solutions, Inc. | — | Travel and Lodging | In-kind items and services | $618.81 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 127 | 143 | $44,037 | $10,174 |
| 2022 | 3 | 123 | 130 | $36,391 | $9,352 |
| 2021 | 3 | 85 | 91 | $21,410 | $6,757 |
| 2020 | 4 | 123 | 138 | $30,258 | $8,200 |
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 73 | 88 | $25,625 | $5,823 | 22.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 39 | 39 | $15,078 | $3,669 | 24.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 16 | $3,334 | $682.14 | 20.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 63 | 70 | $18,351 | $4,791 | 26.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $14,516 | $3,687 | 25.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 20 | 20 | $3,524 | $874.23 | 24.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 36 | 38 | $8,726 | $2,809 | 32.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 24 | 24 | $8,191 | $2,493 | 30.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 25 | 29 | $4,493 | $1,455 | 32.4% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 38 | 38 | $12,616 | $3,536 | 28.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 49 | 61 | $12,375 | $3,220 | 26.0% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 24 | 27 | $3,579 | $981.70 | 27.4% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 12 | 12 | $1,688 | $462.57 | 27.4% |
About Dr. Jonathan Purnell, MD
Dr. Jonathan Purnell, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1144236639.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Purnell, MD has received a total of $209,631 in payments from pharmaceutical and medical device companies, with $27,111 received in 2024. These payments were reported across 109 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($114,034).
As a Medicare-enrolled provider, Purnell has provided services to 458 Medicare beneficiaries, totaling 502 services with total Medicare billing of $34,483. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Portland, OR
- Active Since 08/01/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1144236639
Products in Payments
- Victoza (Drug) $30,006
- Saxenda (Drug) $15,736
- Livalo (Drug) $341.67
- Wegovy (Drug) $154.43
- JANUVIA (Drug) $142.21
- ZEPBOUND (Drug) $117.27
- Repatha (Biological) $90.00
- CONTRAVE (Drug) $23.88
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Portland
Mr. Michael Mcclung, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $1.6M
James Neifing, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $475,019
Maria Fleseriu, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $418,716
Rodica Busui, Md, Phd, MD, PHD
Endocrinology, Diabetes & Metabolism — Payments: $211,479
Nancy Curosh, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $194,307
Andrew Ahmann, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $109,693